Literature DB >> 32835374

Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer.

Priyanka Sharma1,2, Tadanobu Shimura1, Jasjit K Banwait1, Ajay Goel1,2.   

Abstract

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality in the USA. As much as 50-60% of CRC patients develop resistance to 5-fluorouracil (5FU)-based chemotherapeutic regimens, attributing the increased overall morbidity and mortality. In view of the growing evidence that active principles in various naturally occurring botanicals can facilitate chemosensitization in cancer cells, herein, we undertook a comprehensive effort in interrogating the activity of one such botanical-andrographis-by analyzing its activity in CRC cell lines [both sensitive and 5FU resistant (5FUR)], a xenograft animal model and patient-derived tumor organoids. We observed that combined treatment with andrographis was synergistic and resulted in a significant and dose-dependent increase in the efficacy of 5FU in HCT116 and SW480 5FUR cells (P < 0.05), reduced clonogenic formation (P < 0.01) and increased rates of caspase-9-mediated apoptosis (P < 0.05). The genomewide expression analysis in cell lines led us to uncover that activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways were the key mediators for the anti-cancer and chemosensitizing effects of andrographis. Subsequently, we validated our findings in a xenograft animal model, as well as two independent CRC patient-derived organoids-which confirmed that combined treatment with andrographis was significantly more effective than 5FU and andrographis alone and that these effects were in part orchestrated through dysregulated expression of key genes (including HMOX1, GCLC, GCLM and TCF7L2) within the ferroptosis and Wnt-signaling pathways. Collectively, our data highlight that andrographis might offer a safe and inexpensive adjunctive therapeutic option in the management of CRC patients.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32835374      PMCID: PMC7566354          DOI: 10.1093/carcin/bgaa090

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  55 in total

1.  When less is more.

Authors:  Jocelyn Kaiser
Journal:  Science       Date:  2017-03-17       Impact factor: 47.728

2.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  Antiproliferative and Apoptotic Properties of Andrographolide Against Human Colon Cancer DLD1 Cell Line.

Authors:  Imran Khan; Sadaf Mahfooz; Irfan A Ansari
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

5.  Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.

Authors:  Jong-Lyel Roh; Eun Hye Kim; Hye Jin Jang; Jin Young Park; Daiha Shin
Journal:  Cancer Lett       Date:  2016-07-28       Impact factor: 8.679

6.  Effects of 5-FU.

Authors:  Peter M Wigmore; Sarah Mustafa; Maha El-Beltagy; Laura Lyons; Jariya Umka; Geoff Bennett
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 7.  Is there a future for andrographolide to be an anti-inflammatory drug? Deciphering its major mechanisms of action.

Authors:  W S Daniel Tan; Wupeng Liao; Shuo Zhou; W S Fred Wong
Journal:  Biochem Pharmacol       Date:  2017-04-02       Impact factor: 5.858

Review 8.  Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.

Authors:  Ibrahim Halil Sahin; Mehmet Akce; Olatunji Alese; Walid Shaib; Gregory B Lesinski; Bassel El-Rayes; Christina Wu
Journal:  Br J Cancer       Date:  2019-10-14       Impact factor: 7.640

Review 9.  Tumour heterogeneity and the evolution of polyclonal drug resistance.

Authors:  Rebecca A Burrell; Charles Swanton
Journal:  Mol Oncol       Date:  2014-07-10       Impact factor: 6.603

10.  Andrographolide enhances the anti-metastatic effect of radiation in Ras-transformed cells via suppression of ERK-mediated MMP-2 activity.

Authors:  Chih-Chia Yu; Chien-An Chen; Shu-Ling Fu; Hon-Yi Lin; Moon-Sing Lee; Wen-Yen Chiou; Yu-Chieh Su; Shih-Kai Hung
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

View more
  19 in total

Review 1.  Natural medicinal ingredients induce tumor ferroptosis and related mechanisms.

Authors:  Zixue Xuan; Yiwen Zhang; Zongfu Pan; Xiaowei Zheng; Ping Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

Review 2.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

3.  Ferroptosis-Associated Molecular Features to Aid Patient Clinical Prognosis and Therapy Across Human Cancers.

Authors:  Kaisa Cui; Liang Gong; Kang Wang; Yuanben Wang; Liuying Huang; Bingxin Liu; Qilin Li; Qiang Zhang; Bojian Fei; Zhaohui Huang
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

4.  A combined treatment with melatonin and andrographis promotes autophagy and anticancer activity in colorectal cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Carcinogenesis       Date:  2022-04-25       Impact factor: 4.741

5.  Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.

Authors:  Yinghui Zhao; Chuanxin Wang; Ajay Goel
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

6.  Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.

Authors:  Milene Volpato; Nicola Ingram; Sarah L Perry; Jade Spencer; Amanda D Race; Catriona Marshall; John M Hutchinson; Anna Nicolaou; Paul M Loadman; P Louise Coletta; Mark A Hull
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-11       Impact factor: 3.333

7.  Identification the ferroptosis-related gene signature in patients with esophageal adenocarcinoma.

Authors:  Lei Zhu; Fugui Yang; Lingwei Wang; Lin Dong; Zhiyuan Huang; Guangxue Wang; Guohan Chen; Qinchuan Li
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

8.  Role of ferroptosis-related genes in prognostic prediction and tumor immune microenvironment in colorectal carcinoma.

Authors:  Chao Yang; Shuoyang Huang; Fengyu Cao; Yongbin Zheng
Journal:  PeerJ       Date:  2021-07-14       Impact factor: 2.984

9.  Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.

Authors:  Taisheng Liu; Honglian Luo; Jinye Zhang; Xiaoshan Hu; Jian Zhang
Journal:  BMC Cancer       Date:  2021-07-06       Impact factor: 4.430

10.  Development and validation of a ferroptosis-related lncRNAs prognosis signature in colon cancer.

Authors:  Hua-Jun Cai; Zhi-Cheng Zhuang; Yong Wu; Yi-Yi Zhang; Xing Liu; Jin-Fu Zhuang; Yuan-Feng Yang; Yuan Gao; Bin Chen; Guo-Xian Guan
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.